Two recent meetings supported by the ACR Research and Education Foundation (REF) provided investigators in disease-targeted research initiatives the opportunity to present on their progress and build collaborations.
ACR/ARHP Annual Scientific Meeting Plenary Highlights Targets and Treatments for Several Diseases
Promising therapeutic targets for rheumatic diseases were the focus of a plenary session here at the ACR/ARHP 2011 Annual Scientific Meeting in November. Presenters discussed discoveries and treatments for systemic sclerosis, rheumatoid arthritis, vasculitis, and Behçet’s disease.
Rheumatoid Arthritis Drugs May Cut Cardiovascular Risk
Other studies at the ACR/ARHP Annual Scientific Meeting in November examined arthritis treatment, scleroderma screening.
Where Will Kinase Inhibitors Fit into the RA Treatment Mix?
Presenters at “Looking Ahead to Kinase Inhibition in Rheumatoid Arthritis,” a session here at the 2011 ACR/ARHP Annual Scientific Meeting, delved into some of the big questions that rheumatology faces with kinase inhibitor use.
Link between Autoimmunity and Environmental Exposure Needs Further Research
Rheumatology needs further cost-effective and validated methods to track the connection between environmental exposure and autoimmune diseases, including research on phenotypes, genotypes, the synergy between multiple infectious and noninfectious exposures, the timing of exposure, and the mechanisms involved, according to presenters of “Impact of Environmental Health on Autoimmunity,” a session here at the 2011 ACR/ARHP Annual Scientific Meeting held in Chicago in November 2011.
Scientists Pinpoint Three HLA Proteins Linked to Seropositive Rheumatoid Arthritis
Researchers have identified five amino acids in three HLA proteins that explain most of the association between major histocompatibility complex (MHC) and seropositive rheumatoid arthritis (RA).
A Patient’s Perspective on RA
I was diagnosed in April 2010, at 44 years old, with seropositive RA; the disease rapidly turned my life upside down.
Letter: RA Approval for IL-1Ra
Investors convinced the executives of Synergen that they needed to evaluate IL-1Ra for a disease with a more rapid outcome. RA studies were too slow to yield a quick profit. Thus, they picked sepsis syndrome.
A Short History of Rheumatoid Arthritis Therapeutics
Or, why I chose to become a rheumatologist
Give Rheumatology Patients a Helping Hand
Nearly 10 million Americans suffer from carpal tunnel syndrome, a condition that disables a key nerve in the wrist resulting in numbness, tingling, weakness, and loss of function in the hands and wrist. These symptoms are similar to those of rheumatoid arthritis and other rheumatic conditions, and it is important that patients know the difference.
- « Previous Page
- 1
- …
- 62
- 63
- 64
- 65
- 66
- …
- 74
- Next Page »